Anti-p53 antibodies in serum: Relationship to tumor biology and prognosis of breast cancer patients

Medical Oncology

Volumn 27, Issue 3, 2010, Pages 887-893

  Kulic A ^a,b   Sirotkovic Skerlev M ^a,b   Jelisavac Cosic S ^a,b   Herceg, D ^a   Kovac Z ^a,b   Vrbanec, D ^a  

^a KBC Zagreb   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Anti p53 antibodies; Breast cancer; Clinicopathological correlation; Prognosis

Indexed keywords

ANTIBODY; CATHEPSIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53; PROTEIN P53 ANTIBODY; STEROID RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ANTIBODY DETECTION; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER GRADING; CANCER SURVIVAL; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

ADULT; AGED; AUTOANTIBODIES; AUTOANTIGENS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CATHEPSIN D; CELL DIFFERENTIATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM PROTEINS; PHENOTYPE; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77956925139     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9301-1     Document Type: Article

References (48)

1. CA Finlay PW Hinds AJ Levine 1989 The p53 proto-oncogene can act as a suppressor of transformation Cell 57 1083 1093 10.1016/0092-8674(89)90045-7 2525423 (Pubitemid 19169804)
2. D Eliyahu D Michalovitz S Eliyahu O Pinhasi-Kimhi M Oren 1989 Wild-type p53 can inhibit oncogene-mediated focus formation Proc Natl Acad Sci USA 86 8763 8767 10.1073/pnas.86.22.8763 2530586 (Pubitemid 20010305)
3. M Hollstein D Sidransky B Vogelstein CC Harris 1991 p53 mutations in human cancer Science 253 49 53 10.1126/science.1905840 1905840
4. AL Borresen-Dale 2003 TP53 and breast cancer Hum Mutat 21 292 300 10.1002/humu.10174 12619115 (Pubitemid 36292971)
5. B Vogelstein D Lane AJ Levine 2000 Surfing the p53 network Nature 408 307 310 10.1038/35042675 11099028
6. DP Lane 1992 p53, guardian of the genome Nature 358 15 16 10.1038/358015a0 1614522
7. AJ Levine 1997 p53, the cellular gatekeeper for growth and division Cell 88 323 331 10.1016/S0092-8674(00)81871-1 9039259 (Pubitemid 27131374)
8. KM Dameron OV Volpert MA Tainsky N Bouck 1994 Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1 Science 265 1582 1584 10.1126/science.7521539 7521539
9. D Hanahan RA Weinberg 2000 The hallmarks of cancer Cell 100 57 70 10.1016/S0092-8674(00)81683-9 10647931
10. AM Davidoff PA Humphrey JD Iglehart JR Marks 1991 Genetic basis for p53 overexpression in human breast cancer Proc Natl Acad Sci USA 88 5006 5010 10.1073/pnas.88.11.5006 2052583
11. GA Balogh, et al. 2006 Mutant p53 protein in serum could be used as a molecular marker in human breast cancer Int J Oncol 28 4 995 1002 16525651
12. K Angelopoulou, et al. 1994 Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancer Int J Cancer 58 480 487 10.1002/ijc.2910580404 8056443
13. R Lubin, et al. 1995 p53 antibodies in patients with various types of cancer: assay, identification, and characterization Clin Cancer Res 1 1463 1469 9815945
14. T Soussi 2000 p53 antibodies in the sera of patients with various types of cancer: a review Cancer Res 60 1777 1788 10766157
15. H Shimada T Ochiai F Nomura 2003 Titration of serum p53 antibodies in 1085 patients with various types of malignant tumors Cancer 97 682 689 10.1002/cncr.11092 12548611 (Pubitemid 36125846)
16. RF Fonseca, et al. 2003 Anti-p53 antibodies in Brazilian brain tumor patients Genet Mol Res 2 185 190 14966683
17. F Bray P McCarron DM Parkin 2004 The changing global patterns of female breast cancer incidence and mortality Breast Cancer Res 6 229 239 10.1186/bcr932 15535852 (Pubitemid 39440251)
18. J Ferlay M Autier M Boniol M Heanue CP Boyle 2007 Estimates of the cancer incidence and mortality in Europe in 2006 Ann Oncol 18 581 592 10.1093/annonc/mdl498 17287242 (Pubitemid 46359643)
19. Znaor A. Breast cancer in Croatia-where are we now and what do we expect [in Croatian]. HCJZ 2008; 4: January 7, Available at: http://www.hcjz.hr/clanak. php?id=13572.
20. Croatian Health Service, Cancer Registry: cancer incidence in Croatia in 2006 [in Croatian]. Bulletin no.31, Available at: http://www.hzjz.hr/rak/novo. htm.
21. HJ Bloom WW Richardson 1957 Histological grading and prognosis in breast cancer: a study of 1409 cases of which 359 have been followed for 15 years Br J Cancer 11 359 377 13499785
22. R Romić-Stojković S Gamulin 1980 Relationship of cytoplasmic and nuclear estrogen and progesteron receptor in human breast cancer Cancer Res 40 4821 4825 7438115
23. LV Crawford DC Pim RD Bulbrook 1982 Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer Int J Cancer 30 403 408 10.1002/ijc.2910300404 6292117 (Pubitemid 12003724)
24. B Vojtesek, et al. 1995 Absence of p53 autoantibodies in a significant proportion of breast cancer patients Br J Cancer 71 1253 1256 7779720
25. JP Peyrat, et al. 1995 Prognostic significance of circulating p53 antibodies in patients undergoing surgery for locoregional breast cancer Lancet 345 621 622 10.1016/S0140-6736(95)90523-5 7898180
26. RJ Gao, et al. 2005 The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameter Breast Cancer Res Treat 93 111 115 10.1007/s10549-005-4321-9 16187230 (Pubitemid 41396772)
27. B Mudenda, et al. 1994 The relationship between serum p53 autoantibodies and characteristics of human breast cancer Br J Cancer 69 1115 1119 8198980
28. M Müller, et al. 2006 Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers Int J Oncol 29 973 980 16964393
29. S Regele FD Vogl T Kohler R Kreienberg IB Runnebaum 2003 p53 autoantibodies can be indicative of the development of breast cancer relapse Anticancer Res 23 761 764 12680180
30. PC Wilsher, et al. 1996 The significance of p53 autoantibodies in the serum of patients with breast cancer Anticancer Res 16 927 930
31. AM Davidoff JD Iglehart JR Marks 1992 Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers Proc Natl Acad Sci USA 89 3439 3442 10.1073/pnas.89.8.3439 1373500
32. W Lutz E Nowakowska-Swirta 2002 Gene p53 mutations, protein p53, and anti-p53 antibodies as biomarkers of cancer process Int J Occup Med Environ Health 15 209 218 12462448
33. S Labrecque N Naor D Thomson G Matlashewski 1993 Analysis of the anti-p53 antibody response in cancer patients Cancer Res 53 3468 3471 8339249
34. SF Winter, et al. 1992 Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation Cancer Res 52 4168 4174 1322237
35. S Sangrajrang, et al. 2003 Serum p53 antibodies in correlation to other biological parameters of breast cancer Cancer Detect Prev 27 182 186 10.1016/S0361-090X(03)00066-7 12787724 (Pubitemid 36708579)
36. PA Regidor M Regidor R Callies AE Schindler 1996 Detection of p53 auto-antibodies in the sera of breast cancer patients with a new recurrence using an ELISA assay. Does a correlation with the recurrence free interval exist Eur J Gynaecol Oncol 17 192 199 8780917
37. B Schlichtholz, et al. 1992 The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot Cancer Res 52 6380 6384 1423285
38. JA Foekens, et al. 1999 Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients Br J Cancer 79 300 307 10.1038/sj.bjc.6690048 9888472
39. B Tetu, et al. 1999 Cathepsin D expression by cancer and stromal cells in breast cancer: an immunohistochemical study of 1348 cases Breast Cancer Res Treat 55 137 147 10.1023/A:1006140213493 10481941
40. WQ Zheng LM Looi PL Cheah 2002 Correlation between laminin and cathepsin D expression in breast carcinoma Tumori 88 296 299 12400981
41. L Harris, et al. 2007 American society of clinical oncology 2007 update recommendations for the use of tumor markers in breast cancer J Clin Oncol 25 5287 5312 10.1200/JCO.2007.14.2364 17954709 (Pubitemid 350232263)
42. EM Berns, et al. 2000 Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer Cancer Res 60 2155 2162 10786679
43. PO Chappius, et al. 1999 Prognostic significance of p53 mutation in breast cancer frequent detection of non-missense mutations by yeast functional assay Int J Cancer 84 587 593 10.1002/(SICI)1097-0215(19991222)84:6<587::AID- IJC8>3.0.CO;2-8
44. AK Agrawal, et al. 2008 Molecular markers (c-erbB2, p53) in breast cancer Folia Histochem Cytobiol 46 449 455 10.2478/v10042-008-0059-7 19141397
45. P Hammel, et al. 1997 Detection and monitoring of serum p53 antibodies in patients with colorectal cancer Gut 40 356 361 9135525
46. P Lenner, et al. 1999 Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study Br J Cancer 79 927 932 10.1038/sj.bjc.6690148 10070892 (Pubitemid 29082128)
47. F Porzolt M Schmid D Hoher R Muche W Gaus M Montenarh 1994 Biologic relevance of auto-antibodies against p53 in patients with metastatic breast cancer Onkologie 17 402 408 10.1159/000218446
48. H Bao, et al. 2008 Predictive value of serum ant-p53 antibodies, carcino-embryonic antigen, carbohydrate antigen 15-3, estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in taxane-based and anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer patients Anticancer Drugs 19 317 323 10.1097/CAD. 0b013e3282f3d018 18510179